Paul Tudor Jones’s Larimar Therapeutics LRMR Stock Holding History

Paul Tudor Jones’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,223	Closed	-$49K	–	1524
2016 Q3	$49K	Sell	1,223 -29	-2%	-$1.32K	﹤0.01%	1372
2016 Q2	$90K	Sell	1,252 -58	-4%	-$4.58K	﹤0.01%	1524
2016 Q1	$105K	Sell	1,310 -8,004	-86%	-$632K	﹤0.01%	1612
2015 Q4	$703K	Buy	9,314 +8,003	+610%	+$1.29M	0.02%	660
2015 Q3	$502K	Buy	1,311 +378	+41%	+$170K	0.02%	782
2015 Q2	$388K	Sell	933 -438	-32%	-$183K	0.01%	942
2015 Q1	$652K	Buy	+1,371	New	+$651K	0.02%	591

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Paul Tudor Jones's LRMR Position: Q4 2016 in Review

Paul Tudor Jones sold out of Larimar Therapeutics (LRMR) in Q4 2016, closing a stake of 1,223 shares — an estimated $49K sold.

Paul Tudor Jones first reported a position in LRMR in Q1 2015 and held it in 7 quarters. The position peaked at $703K in Q4 2015. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

Paul Tudor Jones reported no remaining Larimar Therapeutics position as of Q4 2016 after selling out during the quarter.
Paul Tudor Jones sold 1,223 Larimar Therapeutics shares in Q4 2016, an estimated $49K.
Paul Tudor Jones first reported a position in Larimar Therapeutics in Q1 2015 and held it in 7 quarters.
Paul Tudor Jones's Larimar Therapeutics position peaked at $703K in Q4 2015.
81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on Tudor Investment Corp's 13F filing for Q4 2016, filed 14 Feb 2017.